idiyopatik parkinson hastalığında huzursuz bacak sendromunun

46.Turjanski N, Lees AJ, Brooks DJ. Striatal dopaminergic function in restless legs
syndrome: 18F-dopa and 11C-lacrapride PET studies. Neurology. 1999;52:932-937.
47.Ruottinen HM, Partinen M, Hublin C. An FDOPA PET study in patients with periodic
limb movement disorders and restless legs syndrome. Neurology. 2000;54:502-504.
48.Early CY, Allen RP, Beard JL. İnsight into the pathophysiology of restless legs
syndrome. J Neurosci Res. 2000;62:623-628.
49.Scales WE, Vander AJ, Brown MB. Human circadian rhythms in temperature, trace
metals, and blood variables. J Appl Phsiol. 1988;65:1840-1846.
50.Targuni B. İron metabolism:Clinical chronobiological aspects. Choronobiolagica.
1978;5:315-336.
51.Chokroverty S, Hening W, Walters A. Restless Legs Syndrome-İnroduction. Sleep and
Movement Disorders. 2003;27:312-315.
52.Allen RP, Earley CJ. Validation of the Jhons Hopkins Restless Legs Severity Scale
(JHRLSS). Sleep Med. 2001;3:239.
53.Hening WA, Walters AS, Rosen R. The İnternational RLS Gruop Rating Scale: a
reliable and valid instrument for assesing severity of the restless legs syndrome.
Neurology. 2001;56(Suppl 3):A4.
54.Trenkwalder C, Brandenburg U, Hundemer H. A randomized long-term placebocontrolled
multicenter trial of pergolide in the treatment of restless legs syndrome with
cenral evaluation of polisomnographic data. Neurology. 2001; (8 suppl 3):AS.
55.Montplaisir J, Denesle R, Petit D. Pramipexole in the treatment of restless legs
syndrome: A follow-up study (in process citation). Eur J Neurol. 2000;7 (Suppl 1):27.
56.Parkinson J. An essay on the shaking palsy. London Sherwood, Neely & Jones
1817;66.
57.Duvasion RC. History of Parkinsonizm. Pharmachology and Therapeutics. 1937;32:1-
17.
58.Bakaç G. Parkinson Hastalığı. Çeviri. Parkinson hastalığının epidemiyolojisi, Editörler:
44